Navigation Links
Ipsen Biopharmaceuticals Joins National Pharmaceutical Council

WASHINGTON, March 28, 2017 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Ipsen Biopharmaceuticals, Inc. has joined the health policy research organization as its newest member. David Cox, PhD, Vice President, Medical and Regulatory Affairs (North America), will serve as his company's representative on NPC's Board of Directors.

"We're pleased to have Ipsen and Dr. Cox join NPC as members," said NPC President Dan Leonard. "We welcome their insights in helping us identify and address health care priorities in today's rapidly changing policy environment."

Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen, a global specialty-driven pharmaceutical group focused on discovering, developing and commercializing new therapeutic options for oncologic, neurologic and endocrine diseases.

"At a time when all of us in health care are facing a number of challenges, we appreciate NPC's thoughtful, research-oriented approach in considering how to improve health system efficiencies and lower access barriers to high-value care, among other issues," said Dr. Cox. "We're looking forward to engaging with NPC on these important health care matters."

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit and follow NPC on Twitter @npcnow.

About Ipsen in North America
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen, a global specialty-driven pharmaceutical group. The U.S. head office is located in Basking Ridge, New Jersey. Ipsen Biopharmaceuticals Canada, Inc. is an integrated business unit within North America and has its head office located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen U.S. research and development center focused on peptide research in oncology and endocrinology, is located in Cambridge, Massachusetts. At Ipsen Bioscience, we focus on creating a highly cooperative and passionate R&D organization through partnerships, innovation, and continuous learning to effectively deliver new treatments for patients. At Ipsen, we focus our resources, investments, and energy on discovering, developing, and commercializing new therapeutic options for oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America, please visit or


To view the original version on PR Newswire, visit:

SOURCE National Pharmaceutical Council
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. New 62,600 Square Foot Lease At 650 East Kendall Street Signed By Ipsen And BioMed Realty
2. Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
3. Ipsen and EpiVax collaborate to produce next generation botulinum toxins
4. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
5. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
6. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
7. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
10. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
11. Biopharmaceuticals - A Global Market Overview
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Personal eye wash is a basic first aid ... at a time. So which eye do you rinse first if a dangerous substance enters ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its dirt ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
Breaking Biology News(10 mins):